CytomX Therapeutics CTMX Increase Decrease In Accrued And Other Liabilities Noncurrent
Increase Decrease In Accrued And Other Liabilities Noncurrent at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept ctmx:IncreaseDecreaseInAccruedAndOtherLiabilitiesNoncurrent.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's increase decrease in accrued and other liabilities noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's increase decrease in accrued and other liabilities noncurrent?
- CytomX Therapeutics (CTMX) reported increase decrease in accrued and other liabilities noncurrent of -$3.6M in Q1 2026.
- How has CytomX Therapeutics's increase decrease in accrued and other liabilities noncurrent changed year-over-year?
- CytomX Therapeutics's increase decrease in accrued and other liabilities noncurrent decreased by 70.9% year-over-year, from -$2.11M to -$3.6M.
- What does increase decrease in accrued and other liabilities noncurrent mean?
- This metric tracks the net change in long-term accrued liabilities and other non-current obligations that are not classified elsewhere. It serves as an indicator of shifts in long-term operational commitments or deferred obligations. Changes here can signal adjustments in long-term operational strategy or the timing of non-current expense recognition.